EAACI Congress 2025
BackTPS18 - Biologicals 01
Friday 13 Jun, 12:00 PM -
13:00 PM Glasgow, United Kingdom
Poster Zone
Thematic Poster Session
D1.368
Anti-interleukin-5 treatment in patients with severe eosinophilic asthma provides consistent symptom control for at least 8 years
D1.369
Characteristics of patients with severe asthma undergoing biological treatment at a reference center
D1.370
Clinical outcomes and quality of life improvement in children with moderate-to-severe atopic dermatitis and atopic multimorbidity treated with dupilumab
D1.367
Dupilumab for refractory pruritus in hematological and non-hematological malignancies – preliminary results
D1.371
Dupilumab for the treatment of refractory severe chronic spontaneous urticaria
D1.363
Efficacy and safety of Mepolizumab in treatment of eosinophilic granulomatosis with polyangiitis
D1.362
Exploratory Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of YH35324, a Long-Acting high-affinity IgETrap-Fc protein, in Patients with Chronic Spontaneous Urticaria Refractory to Omalizumab
D1.366
Improvement Over Time in Specific Aspects of Quality of Life in Patients with Chronic Spontaneous Urticaria Treated with Omalizumab
D1.364
Update on the Observed incidence of Anaphylaxis and Serum Sickness in Patients Receiving Omalizumab in a Canadian Tertiary Allergy/Asthma Clinic
D1.365
ZL-1503: A Bispecific Antibody Targeting Inflammatory and Pruritogenic Pathways with a Prolonged Serum Half-life and Sustained Activity in Non-human Primates
